Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02373280 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 2024 to Apr 2027
    • Study completion date: Dec 2024 to Dec 2027
    v8
  2. Primary completion date: Dec 2022 to Apr 2024
    • Study completion date: Dec 2022 to Dec 2024
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Primary and study completion dates: Dec 2019 to Dec 2022v5
  5. Enrollment target: 400 to 600v4 Show 5 more changesShow less
    • Primary completion date: Nov 2017 to Dec 2019
    • Trial status: Enrolling by Invitation to Recruiting
    • Study completion date: Dec 2017 to Dec 2019
    • Interventions: 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole) (Drug), 7 day tailored therapy based on antimicrobial… to 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole) (Drug), 7 day moxifloxacin based triple therapy…
    • Site details revised
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Jul 2016 to Nov 2017
    • Study completion date: Jul 2016 to Dec 2017
    v3
  2. Trial status: Recruiting to Enrolling by Invitation
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
Trial Details
NCT Number NCT02373280
Lead Sponsor Seoul National University Bundang Hospital
Conditions
(from sponsor)		 Helicobacter Infection
Related terms Helicobacter Infections
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov